A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group Study (E2392)

Richard Hellman; Donna S. Neuberg; Henry Wagner; Margaret Grunnet; H. Ian Robins; Daniel Karp; Patrick Flynn; George Adams

doi:10.1023/A:1005867520788

A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group Study (E2392)

Richard Hellman, Donna S. Neuberg, Henry Wagner, Margaret Grunnet, H. Ian Robins, Daniel Karp, Patrick Flynn, George Adams

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas. Thirty three patients (median age 51 years) were entered (27 with glioblastoma multiforme, 6 with anaplastic astrocytoma). Toxicity was manageable with no lethal toxicities. Five of seven life threatening toxicities were hematologic. Median overall survival was 14.2 months. These data suggest this regimen is effective treatment for patients with high grade gliomas.

Original language	English (US)
Pages (from-to)	55-62
Number of pages	8
Journal	Journal of neuro-oncology
Volume	37
Issue number	1
DOIs	https://doi.org/10.1023/A:1005867520788
State	Published - 1998

All Science Journal Classification (ASJC) codes

Oncology
Neurology
Clinical Neurology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1023/A:1005867520788

Cite this

Hellman, R., Neuberg, D. S., Wagner, H., Grunnet, M., Robins, H. I., Karp, D., Flynn, P., & Adams, G. (1998). A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group Study (E2392). Journal of neuro-oncology, 37(1), 55-62. https://doi.org/10.1023/A:1005867520788

@article{8e57b168c0834ae2b5913a884a0e2472,

title = "A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group Study (E2392)",

abstract = "This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas. Thirty three patients (median age 51 years) were entered (27 with glioblastoma multiforme, 6 with anaplastic astrocytoma). Toxicity was manageable with no lethal toxicities. Five of seven life threatening toxicities were hematologic. Median overall survival was 14.2 months. These data suggest this regimen is effective treatment for patients with high grade gliomas.",

author = "Richard Hellman and Neuberg, {Donna S.} and Henry Wagner and Margaret Grunnet and Robins, {H. Ian} and Daniel Karp and Patrick Flynn and George Adams",

note = "Funding Information: This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D., Chair) and supported in part by Public Service grants CA 23318, CA 21076, CA 07190, CA 35267, CA 20365, CA 66636, CA 21115 from the National Cancer Institute, National Institutes of Health, and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.",

year = "1998",

doi = "10.1023/A:1005867520788",

language = "English (US)",

volume = "37",

pages = "55--62",

journal = "Journal of Neuro-Oncology",

issn = "0167-594X",

publisher = "Kluwer Academic Publishers",

number = "1",

}

Hellman, R, Neuberg, DS, Wagner, H, Grunnet, M, Robins, HI, Karp, D, Flynn, P & Adams, G 1998, 'A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group Study (E2392)', Journal of neuro-oncology, vol. 37, no. 1, pp. 55-62. https://doi.org/10.1023/A:1005867520788

A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group Study (E2392). / Hellman, Richard; Neuberg, Donna S.; Wagner, Henry et al.

In: Journal of neuro-oncology, Vol. 37, No. 1, 1998, p. 55-62.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group Study (E2392)

AU - Hellman, Richard

AU - Neuberg, Donna S.

AU - Wagner, Henry

AU - Grunnet, Margaret

AU - Robins, H. Ian

AU - Karp, Daniel

AU - Flynn, Patrick

AU - Adams, George

N1 - Funding Information: This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D., Chair) and supported in part by Public Service grants CA 23318, CA 21076, CA 07190, CA 35267, CA 20365, CA 66636, CA 21115 from the National Cancer Institute, National Institutes of Health, and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

PY - 1998

Y1 - 1998

N2 - This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas. Thirty three patients (median age 51 years) were entered (27 with glioblastoma multiforme, 6 with anaplastic astrocytoma). Toxicity was manageable with no lethal toxicities. Five of seven life threatening toxicities were hematologic. Median overall survival was 14.2 months. These data suggest this regimen is effective treatment for patients with high grade gliomas.

AB - This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas. Thirty three patients (median age 51 years) were entered (27 with glioblastoma multiforme, 6 with anaplastic astrocytoma). Toxicity was manageable with no lethal toxicities. Five of seven life threatening toxicities were hematologic. Median overall survival was 14.2 months. These data suggest this regimen is effective treatment for patients with high grade gliomas.

UR - http://www.scopus.com/inward/record.url?scp=0031882420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031882420&partnerID=8YFLogxK

U2 - 10.1023/A:1005867520788

DO - 10.1023/A:1005867520788

M3 - Article

C2 - 9525838

AN - SCOPUS:0031882420

VL - 37

SP - 55

EP - 62

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -

A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group Study (E2392)

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this